Serial CTC/cfDNA assessment for the identification of pathogenic mutations in patients with breast cancer.

e23070Background: Serial liquid biopsyassessment provides a unique platform for detecting existing and / or emergent resistance mutations; it may be particularly beneficialwhen patients begin to ...